Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& d, a+ D" R3 _! c! j9 t* r
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 + r. k: L6 g1 N7 t
+ Author Affiliations
, M/ h7 v4 W: P, u% G
4 O/ e A' L; M+ o# \& A' U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 5 [. s6 i8 R/ Z# U; m3 Y
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 q# I8 x3 D K/ @# ^
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan & H, ^) F: H/ n
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
1 G9 } v5 ^9 k9 |4 g$ \5 |' c5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
0 ~2 Y$ ^" }* u$ E2 r6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
9 d2 B) n& q+ v' m. ]5 W6 `7Kinki University School of Medicine, Osaka 589-8511, Japan
2 i0 D; J) ?' c2 s8Izumi Municipal Hospital, Osaka 594-0071, Japan , V7 q' N3 P! Z5 Z. O/ n0 s, A* u
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan " r) I: U1 F; U- G9 Y- E0 Y
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp & i1 ` N- N- `- a3 q
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. + |5 O( G# y; V* N2 M9 `- T
5 K( w5 E. B# f& b, Y( D( V* m |